摘要
目的:观察紫杉醇联合卡培他滨(希罗达)作为二线方案治疗晚期胃癌的有效性和安全性。方法:采用紫杉醇175mg/m^2静脉滴注3h,第1天;希罗达1000mg/m^2,每天2次,第1-14天,21天为1个周期,连用2个周期后评价疗效。结果:30例中,获得完全缓解(CR)2例,占6.7%;部分缓解(PR)12例,占40.0%;稳定(SD)11例,占36.7%;进展(PD)5例,占16.7%。总有效率(CR+PR)为46.7%。不良反应主要为恶心呕吐、骨髓抑制、腹泻、手足综合征及脱发等。结论:紫杉醇联合卡培他滨二线治疗晚期胃癌疗效较高,安全性好。
We evaluated the antitumour activity and toxicities of paclitaxel and capecitabine as therapy in patients with advaneed gastric cancer (AGC). Methods:Patients with histologically confirmed unresectable or metastatic AGC were treated with eapeeitabine 1 000mg/m^2 p. o. twice daily on days 1-14 and paelitaxel 175mg/m^2 i. v. on day 1 every 3 weeks until disease progression or unacceptable toxicities. Results:A total of 2 patients showed complete response and 12 showed partial response making the overall response rate 46.7%. Median time to progression was 6.7 months and median overall survival time was 9.9 months . Grade 3 or 4 adverse events include leukoeytopenia, hand-foot syndrome, CINV, anti alopecia. There was no leukocytopenia fever or treatment-related deaths. Conclusion:Paelitaxel and caoecitabine combination chemotherapy was active and highly tolerable as a therapy for AGC.
出处
《临床肿瘤学杂志》
CAS
2009年第1期68-69,共2页
Chinese Clinical Oncology
关键词
晚期胃癌
紫杉醇
卡培他滨
化学治疗
Advanced gastric cancer
Paclitaxel
Capecitabine
Chemotherapy